FHIT low / pHER2 high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FHIT low / pHER2 high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy

Published:2020-05-13 Issue:2 Volume:251 Page:187-199
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Da Silva Jordan¹,Jouida Amina¹,Ancel Julien¹²,Dalstein Véronique¹³,Routhier Julie¹,Delepine Gonzague¹⁴,Cutrona Jérôme¹,Jonquet Antoine¹,Dewolf Maxime²,Birembaut Philippe¹³,Deslée Gaëtan¹²,Polette Myriam¹³,Nawrocki‐Raby Béatrice¹^ORCID

Affiliation:

1. INSERM Université de Reims Champagne Ardenne, P3Cell UMR‐S 1250, SFR CAP SANTE Reims France

2. CHU de Reims, Hôpital Maison Blanche Service de Pneumologie Reims France

3. CHU de Reims, Hôpital Maison Blanche Laboratoire de Pathologie Reims France

4. CHU de Reims, Hôpital Robert Debré Service de Chirurgie Cardio‐Vasculaire et Thoracique Reims France

Funder

Ligue Contre le Cancer

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/path.5439

Reference42 articles.

1. The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends

2. Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

3. Targeting HER2 for the Treatment of Breast Cancer

4. Breast Cancer Treatment

5. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated analysis of FHIT gene alterations in cancer;Cell Cycle;2024-01-02

2. HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies;Life;2023-12-29

3. Advances and challenges in the treatment of lung cancer;Biomedicine & Pharmacotherapy;2023-12

4. Acetylcholine promotes chronic stress-induced lung adenocarcinoma progression via α5-nAChR/FHIT pathway;Cellular and Molecular Life Sciences;2023-04-07

5. Potential Role of the Fragile Histidine Triad in Cancer Evo-Dev;Cancers;2023-02-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3